Advanced search
1 file | 1.92 MB

A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo

(2017) ANTIVIRAL RESEARCH. 148. p.53-64
Author
Organization
Abstract
Infections with hepatitis C virus (HCV) represent a worldwide health burden and a prophylactic vaccine is still not available. Liver transplantation (LT) is often the only option for patients with HCV-induced end-stage liver disease. However, immediately after transplantation, the liver graft becomes infected by circulating virus, resulting in accelerated progression of liver disease. Although the efficacy of HCV treatment using direct-acting antivirals has improved significantly, immune compromised LT-patients and patients with advanced liver disease remain difficult to treat. As an alternative approach, interfering with viral entry could prevent infection of the donor liver. We generated a human monoclonal antibody (mAb), designated 2A5, which targets the HCV envelope. The neutralizing activity of mAb 2A5 was assessed using multiple prototype and patient-derived HCV pseudoparticles (HCVpp), cell culture produced HCV (HCVcc), and a human-liver chimeric mouse model. Neutralization levels observed for mAb 2A5 were generally high and mostly superior to those obtained with AP33, a well-characterized HCV-neutralizing monoclonal antibody. Using humanized mice, complete protection was observed after genotype la and 4a HCV challenge, while only partial protection was achieved using gt1b and 6a isolates. Epitope mapping revealed that mAb 2A5 binding is conformation-dependent and identified the E2-region spanning amino acids 434 to 446 (epitope II) as the predominant contact domain. Conclusion: mAb 2A5 shows potent anti-HCV neutralizing activity both in vitro and in vivo and could hence represent a valuable candidate to prevent HCV recurrence in LT-patients. In addition, the detailed identification of the neutralizing epitope can be applied for the design of prophylactic HCV vaccines.
Keywords
Hepatitis C virus, Envelope protein, Neutralizing antibody, Chimeric mice, Liver transplantation, Vaccine, HEPATOCELLULAR-CARCINOMA, LIVER-TRANSPLANTATION, HYPERVARIABLE REGION, IMMUNE-RESPONSES, GLYCOPROTEIN E2, HCV, MICE, RECURRENCE, CHALLENGE, THERAPY

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.92 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Desombere, Isabelle, Ahmed Atef Ahmed Abouzeid Mesalam, Richard A Urbanowicz, Freya Van Houtte, Lieven Verhoye, Zhen-Yong Keck, Aliasghar Farhoudi Moghadam, et al. 2017. “A Novel Neutralizing Human Monoclonal Antibody Broadly Abrogates Hepatitis C Virus Infection  in Vitro and in Vivo.” Antiviral Research 148: 53–64.
APA
Desombere, Isabelle, Mesalam, A. A. A. A., Urbanowicz, R. A., Van Houtte, F., Verhoye, L., Keck, Z.-Y., Farhoudi Moghadam, A., et al. (2017). A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection  in vitro and in vivo. ANTIVIRAL RESEARCH, 148, 53–64.
Vancouver
1.
Desombere I, Mesalam AAAA, Urbanowicz RA, Van Houtte F, Verhoye L, Keck Z-Y, et al. A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection  in vitro and in vivo. ANTIVIRAL RESEARCH. 2017;148:53–64.
MLA
Desombere, Isabelle, Ahmed Atef Ahmed Abouzeid Mesalam, Richard A Urbanowicz, et al. “A Novel Neutralizing Human Monoclonal Antibody Broadly Abrogates Hepatitis C Virus Infection  in Vitro and in Vivo.” ANTIVIRAL RESEARCH 148 (2017): 53–64. Print.
@article{8539990,
  abstract     = {Infections with hepatitis C virus (HCV) represent a worldwide health burden and a prophylactic vaccine is still not available. Liver transplantation (LT) is often the only option for patients with HCV-induced end-stage liver disease. However, immediately after transplantation, the liver graft becomes infected by circulating virus, resulting in accelerated progression of liver disease. Although the efficacy of HCV treatment using direct-acting antivirals has improved significantly, immune compromised LT-patients and patients with advanced liver disease remain difficult to treat. As an alternative approach, interfering with viral entry could prevent infection of the donor liver. We generated a human monoclonal antibody (mAb), designated 2A5, which targets the HCV envelope. The neutralizing activity of mAb 2A5 was assessed using multiple prototype and patient-derived HCV pseudoparticles (HCVpp), cell culture produced HCV (HCVcc), and a human-liver chimeric mouse model. Neutralization levels observed for mAb 2A5 were generally high and mostly superior to those obtained with AP33, a well-characterized HCV-neutralizing monoclonal antibody. Using humanized mice, complete protection was observed after genotype la and 4a HCV challenge, while only partial protection was achieved using gt1b and 6a isolates. Epitope mapping revealed that mAb 2A5 binding is conformation-dependent and identified the E2-region spanning amino acids 434 to 446 (epitope II) as the predominant contact domain. Conclusion: mAb 2A5 shows potent anti-HCV neutralizing activity both in vitro and in vivo and could hence represent a valuable candidate to prevent HCV recurrence in LT-patients. In addition, the detailed identification of the neutralizing epitope can be applied for the design of prophylactic HCV vaccines.},
  author       = {Desombere, Isabelle and Mesalam, Ahmed Atef Ahmed Abouzeid and Urbanowicz, Richard A and Van Houtte, Freya and Verhoye, Lieven and Keck, Zhen-Yong and Farhoudi Moghadam, Aliasghar and Vercauteren, Koen and Weening, Karin and Baumert, Thomas F and Patel, Arvind H and Foung, Steven KH and Ball, Jonathan and Leroux-Roels, Geert and Meuleman, Philip},
  issn         = {0166-3542},
  journal      = {ANTIVIRAL RESEARCH},
  language     = {eng},
  pages        = {53--64},
  title        = {A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection  in vitro  and  in vivo},
  url          = {http://dx.doi.org/10.1016/j.antiviral.2017.10.015},
  volume       = {148},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: